Isabl GTM brain

category

market profile

• text: Targeted cancer panels survey a limited part of the genome, motivating broader profiling for patients with less common cancers.
• text: Isabl's government-funded project describes whole-genome and transcriptome analysis for pediatric and rare cancers and biomarker discovery.
• text: The company advertises WGTS software and a GxT diagnostic platform; current clinical availability and company status should be verified.

personas

• title: Molecular pathology laboratory director
  pains:

  • Targeted panels can leave clinically relevant alterations outside the tested regions
  • Broad sequencing requires reliable analysis and turnaround that fits laboratory workflows
• title: Precision oncology program leader
  pains:

  • Rare cancers may yield few useful findings on conventional panels
  • Clinicians need interpretable evidence and validated reporting before adopting new testing
• title: Translational oncology or pharma biomarker lead
  pains:

  • DNA and RNA data must be interpreted together to explore response and resistance
  • Finding rare biomarkers across complex samples requires scalable analysis

icp

• text: Cancer centers and molecular diagnostic laboratories with sequencing capacity and precision oncology programs.
• text: Research and clinical groups investigating pediatric or rare cancers and whole-genome biomarker discovery.
• text: Oncology drug developers seeking molecular markers of treatment response and clinical trial eligibility.

message pillars

• text: Look across the tumor genome and transcriptome rather than a narrow panel.
• text: Support broader identification of potential biomarkers.
• text: Pursue broader access to whole-genome cancer testing.

objections

• objection: Is this test authorized and available for routine clinical use?
  response: Confirm current intended use, regulatory status, laboratory validation and availability directly; breakthrough designation alone is not marketing authorization.
• objection: Can comprehensive sequencing fit clinical turnaround and cost constraints?
  response: Review the actual sample workflow, validation evidence, turnaround, reimbursement and pricing for the proposed use case.
• objection: Can sensitive genomic data be handled within our requirements?
  response: Review current security and data-processing terms for the specific product and deployment before sharing patient data.

competitors

• name: Inocras
  why: Offers cancer and rare disease whole-genome analysis and is identified as a competitor in CB Insights.
• name: Exact Sciences
  why: OncoExTra offers oncology profiling using whole-exome and whole-transcriptome sequencing.
• name: Labcorp
  why: OmniSeq INSIGHT analyzes tumor DNA and RNA for oncology profiling.

influencers

• name: Elli Papaemmanuil
  url: https://healthcareventurecapitalfund.com/companies/isabl/
  why: Scientific co-founder and cancer genomics researcher; her current role should be verified before outreach.

keywords

• cancer whole genome sequencing
• whole transcriptome cancer analysis
• precision oncology genomics
• tumor biomarker discovery
• rare cancer genomic profiling
• pediatric cancer sequencing

voice

• Scientific
• Mission-driven
• Aspirational

signals

• text: A cancer center is expanding molecular profiling beyond targeted panels.
• text: A lab is developing whole-genome and transcriptome workflows for pediatric or rare cancers.
• text: A drug developer is seeking biomarkers associated with response in a cancer trial.

stack

• Illumina sequencing

pricing

motion

channels

• Scientific publications
• Partnerships
• Website

confidence

Founders

• name: Juan Medina
  title: Founder
  role: Founder
  bio: Co-Founder & CTO, Isabl Inc.
• name: Andrew Kung
  title: Founder
  role: Founder
• name: Elli Papaemmanuil
  title: Founder
  role: Founder